Wu Yuhsin, Schomisch Steve J, Cipriano Cassandra, Chak Amitabh, Lash Richard H, Ponsky Jeffrey L, Marks Jeffrey M
Department of Surgery, University Hospitals Case Medical Center, 11100 Euclid Ave., Mail Stop LKS 5047, Cleveland, OH, 44106, USA,
Surg Endosc. 2014 Feb;28(2):447-55. doi: 10.1007/s00464-013-3210-2. Epub 2013 Oct 8.
Esophageal endoscopic submucosal dissection (ESD) is an effective minimally invasive therapy for early esophageal cancer and high-grade Barrett dysplasia. However, esophageal stricture formation after circumferential or large ESD has limited its wide adoption. Mitomycin C (MMC), halofuginone (Hal), and transforming growth factor β3 (TGF-β3) exhibits antiscarring effects that may prevent post-ESD stricture formation.
Using endoscopic mucosectomy (EEM) technique, an 8- to 10-cm-long circumferential esophageal mucosal segment was excised in a porcine model. The site was either untreated (control, n = 6) or received 40 evenly distributed injections of antiscarring agent immediately and at weeks 1 and 2. High and low doses were used: MMC 5 mg (n = 2), 0.5 mg (n = 2); Hal 5 mg (n = 2), 1.5 mg (n = 2), 0.5 mg (n = 2); TGF-β3 2 μg (n = 2), 0.5 μg (n = 2). The degree of stricture formation was determined by the percentage reduction of the esophageal lumen on weekly fluoroscopic examination. Animals were euthanized when strictures exceeded 80 % or the animals were unable to maintain weight.
The control group had a luminal diameter reduction of 78.2 ± 10.9 % by 2 weeks and were euthanized by week 3. Compared at 2 weeks, the Hal group showed a decrease in mean stricture formation (68.4 % low dose, 57.7 % high dose), while both TGF-β3 dosage groups showed no significant change (65.3 % low dose, 76.2 % high dose). MMC was most effective in stricture prevention (53.6 % low dose, 35 % high dose). Of concern, the esophageal wall treated with high-dose MMC appeared to be necrotic and eventually led to perforation. In contrast, low dose MMC, TGF-β3 and Hal treated areas appeared re-epithelialized and healthy.
Preliminary data on MMC and Hal demonstrated promise in reducing esophageal stricture formation after EEM. More animal data are needed to perform adequate statistical analysis in order to determine overall efficacy of antiscarring therapy.
食管内镜黏膜下剥离术(ESD)是治疗早期食管癌和高级别巴雷特异型增生的一种有效的微创治疗方法。然而,环形或大面积ESD术后食管狭窄的形成限制了其广泛应用。丝裂霉素C(MMC)、卤夫酮(Hal)和转化生长因子β3(TGF-β3)具有抗瘢痕形成作用,可能预防ESD术后狭窄的形成。
采用内镜下黏膜切除术(EEM)技术,在猪模型中切除一段长8至10厘米的环形食管黏膜段。该部位要么不进行处理(对照组,n = 6),要么在即刻、第1周和第2周接受40次均匀分布的抗瘢痕形成剂注射。使用了高剂量和低剂量:MMC 5毫克(n = 2)、0.5毫克(n = 2);Hal 5毫克(n = 2)、1.5毫克(n = 2)、0.5毫克(n = 2);TGF-β3 2微克(n = 2)、0.5微克(n = 2)。通过每周的荧光透视检查测定食管腔直径减少的百分比来确定狭窄形成的程度。当狭窄超过80%或动物无法维持体重时对动物实施安乐死。
对照组在2周时管腔直径减少了78.2±10.9%,并在第3周时实施安乐死。在2周时进行比较,Hal组平均狭窄形成有所减少(低剂量组为68.4%,高剂量组为57.7%),而两个TGF-β3剂量组均无显著变化(低剂量组为65.3%,高剂量组为76.2%)。MMC在预防狭窄方面最有效(低剂量组为53.6%,高剂量组为35%)。值得关注的是,高剂量MMC处理的食管壁似乎出现坏死并最终导致穿孔。相比之下,低剂量MMC、TGF-β3和Hal处理的区域似乎重新上皮化且健康。
关于MMC和Hal的初步数据表明其在减少EEM术后食管狭窄形成方面具有前景。需要更多动物数据来进行充分的统计分析,以确定抗瘢痕形成治疗的总体疗效。